Is in vitro-acquired resistance to enzalutamide a useful model? - Wikidata - wikimedia - TriplyDB

Is in vitro-acquired resistance to enzalutamide a useful model?

Is in vitro-acquired resistance to enzalutamide a useful model?

http://www.wikidata.org/entity/Q48658920

about

Is in vitro-acquired resistance to enzalutamide a useful model?

http://www.wikidata.org/entity/Q48658920

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

2014年學術文章

@zh-hant

name

Is in vitro-acquired resistance to enzalutamide a useful model?

@en

Is in vitro-acquired resistance to enzalutamide a useful model?

@nl

type

label

Is in vitro-acquired resistance to enzalutamide a useful model?

@en

Is in vitro-acquired resistance to enzalutamide a useful model?

@nl

prefLabel

Is in vitro-acquired resistance to enzalutamide a useful model?

@en

Is in vitro-acquired resistance to enzalutamide a useful model?

@nl

P1433

Q48658920-867085A5-9DE0-478E-8528-3ABB5555FD5C

P1476

Q48658920-5BE29B21-381C-4CF3-8A2D-278B55E44E9E

P2093

Q48658920-7CC8B22C-B5C5-4873-83DB-FA5EF513F3A9

P2860

Q48658920-027B4AA0-6493-4F80-8786-7D43109082A9

Q48658920-119F468E-B8B9-4AEB-AAFB-274E4E8CD251

Q48658920-3697348A-ED2B-424F-8C64-88D06F6CE4B8

Q48658920-3A39B5FA-1ED0-4082-98C7-95CCF7F4A72A

Q48658920-4CF8C8F1-2F0F-4502-AC18-C01B78184C8B

Q48658920-744364C0-B117-4D22-874E-490BEE3BADFA

Q48658920-90E89864-72FB-4D1E-93CD-18CA4241D194

Q48658920-95DD95AE-80BA-4A3B-B93A-B90B2CDE4A8E

Q48658920-9A9D59B0-5532-48F3-83F5-388DCD7331F3

Q48658920-9D8CE142-B6A0-4A21-876B-B2AC3879D2EA

P304

Q48658920-F5C7EC19-7341-42B1-B52B-AAFB36B48BA6

P31

Q48658920-4D60B4FF-9353-4968-98EB-347C739A7CA8

Q48658920-c4ec6b04-a716-405a-9d92-223fa76a5073

P356

Q48658920-F378F1C8-4CC6-44CD-BFDF-7E2A02CB44EC

P407

Q48658920-A5AC5F88-7B99-44E0-985B-90B598DABA6A

P433

Q48658920-98A145A4-9D98-4C5D-B22A-AA7932AD1F02

P478

Q48658920-FF8D2398-89F8-48AC-A1C8-B3E654D7DCA0

P50

Q48658920-230265EF-07E8-433A-9883-5DE9C4CD56D8

P577

Q48658920-00C6A4C7-859A-4900-966C-124F9F883EE7

P698

Q48658920-716E59D1-3EE6-4E14-9C81-9866F72B5B6A

P356

P1433

Future Oncology

P1476

Is in vitro-acquired resistance to enzalutamide a useful model?

@en

P2093

Giuseppe Di Lorenzo

http://www.w3.org/2001/XMLSchema#string

P2860

Sipuleucel-T (Provenge®) for castration-resistant prostate cancer

One mouse, one patient paradigm: New avatars of personalized cancer therapy

Prostate Health Index (Phi) and Prostate Cancer Antigen 3 (PCA3) significantly improve prostate cancer detection at initial biopsy in a total PSA range of 2-10 ng/ml

Hormone-refractory prostate cancer: where are we going?

Platinum-based chemotherapy for variant castrate-resistant prostate cancer.

New perspectives in the therapy of castration resistant prostate cancer.

Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer.

Radium 223 dichloride: a multidisciplinary approach to metastatic castration-resistant prostate cancer.

Carboplatin plus etoposide in heavily pretreated castration-resistant prostate cancer patients.

Potential value of Gleason score in predicting the benefit of cabazitaxel in metastatic castration-resistant prostate cancer.

P304

2551-2553

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/FON.14.212

http://www.w3.org/2001/XMLSchema#string

P407

P433

16

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25531044

http://www.w3.org/2001/XMLSchema#string